Bon Jovi enlists in Advil's battle with Tylenol

Share this article:
Bon Jovi enlists in Advil's battle with Tylenol
Bon Jovi enlists in Advil's battle with Tylenol
Jon Bon Jovi is the latest celebrity pitchman for Pfizer Consumer Healthcare's Advil.

The ‘80s hard rocker, now entering his fifties, cut a 30-second testimonial for Pfizer's OTC painkiller, quipping “pain does not have much of a place in my life. I checked the schedule and it's not on it.” Bon Jovi, it seems, became an Advil loyalist after he injured his calf muscle onstage in New Jersey last year. Additional digital content from the taping is up on TakeAdvil.com, which also features testimonials from Regis and Joy Philbin, along with a host of non-famous people, as well as content touting the Jon Bon Jovi Soul Foundation.  

The campaign, which launched last year with TV, print and web ads, takes direct aim at J&J's rival Tylenol, with spots opening with a narrator saying: “Every day, thousands of people are switching from Tylenol to Advil.”

“Our Advil Stories campaign emphasizes that everyone experiences physicial pain for some reason in their lives, no matter who they are,” said Srini Sripada, senior director, pain management for Pfizer Consumer Healthcare, in a statement. “We know that Advil consumers are our greatest ambassadors and that pain is something we all share.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...